RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reaction...
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28 th , 2026, marking the company’s readiness to serve Canadian patients...
Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide...
Barchart Research What to Expect from RDY Earnings RDY Generated May 7, 2026 Current Price $13.43 EPS Estimate $$0.09 Consensus Rating Moderate Sell Average Move 2.59% Dr. Reddy's Reports Tuesday With...
Dr. Reddy’s becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada The market authorization was granted...
Following the submission in December 2025, USFDA has accepted Dr. Reddy’s 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine...
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts...